research Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
Search
for
Sort by
Research
270-300 / 1000+ results
research Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
Upadacitinib may effectively treat alopecia areata without side effects.
research Effectiveness of Oral Tofacitinib Treatment on Patients With Moderate-to-Severe Alopecia Areata in Iran
Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
research Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
research Treatment Modalities for Lymphocytic and Neutrophilic Scarring Alopecia
Early treatment is key for permanent hair loss disorders, with options ranging from medications and phototherapy to immunomodulators and antibiotics, depending on severity and type.
research Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry About?
People with alopecia areata may have a higher risk of blood clots.
research Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata
Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
research A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata
Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
research Reply to Early Onset Effluvium Secondary to COVID-19 and Body-Hair Effluvium
COVID-19 can cause different types of hair loss, which may last up to 100 days, and treatments are still being explored.
research Recalcitrant Lichen Planopilaris Treated with Upadacitinib: A Case Series
Upadacitinib may effectively treat resistant lichen planopilaris.
research Common Causes of Hair Loss
Hair loss can be caused by hormones, illness, autoimmune disorders, or vitamin deficiencies, and treatments vary depending on the type.
research Tofacitinib for the Treatment of Three Immune-Mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
research Janus Kinase Inhibitors for the Use of Alopecia Areata: A Promising Therapeutic of the Future
JAK inhibitors show promise as a future treatment for hair loss.
research Efficacy of Janus Kinase Inhibitors in Adult Patients With Alopecia Areata
Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
research Janus Kinase (JAK) Inhibitors in Treating Alopecia Areata (AA)
JAK inhibitors may help treat alopecia areata and promote hair regrowth.
research Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
research Janus Kinase Inhibitors Versus Other Biological Treatments in Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
research Observational Real-World Evidence on the Efficacy and Safety of Janus Kinase Inhibitors in the Treatment of Moderate to Severe Active Ulcerative Colitis
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report
Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
research The Diagnosis and Treatment of Hair and Scalp Diseases
Hair loss requires customized treatments based on its various causes and types.
research Alopecias in Humans: Biology, Pathomechanisms, and Emerging Therapies
New treatments for hair loss are emerging as we better understand hair growth and its genetic causes.
research Advances in Topical Therapies for Clinically Relevant and Prevalent Forms of Alopecia
Topical treatments like minoxidil and corticosteroids are effective for hair loss, with JAK inhibitors promising for alopecia areata.
research The Usefulness and Wellbeing of Tofacitinib in the Treatment of Alopecia Areata
Tofacitinib is effective and safe for treating alopecia areata.
research Alopecia Areata: A Review of Diagnosis, Pathogenesis, and the Therapeutic Landscape
New treatments for alopecia areata show promise, but standardized guidelines are needed.
research Alopecia Areata: Multifactorial Disease Involving Genetic, Environmental, and Autoimmune Factors
Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.
research Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated with Alopecia Universalis
Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
research What's New in the Treatment of Hair Loss?
New treatments for hair loss, like JAK inhibitors, PRP, anti-androgens, and minoxidil, offer better options.
research PSS20 Mediation Modeling and Measurement Characteristics of the Itch Severity Score from a Phase 2B Trial of Oral CP-690-550 in Patients with Moderate-to-Severe Plaque Psoriasis
CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
research Treatment of Refractory Folliculitis Decalvans With the Topical JAK Inhibitor Tofacitinib
Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
research What Is Behind the 'Swarm of Bees' in Alopecia Areata
Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.